NCT02345161: A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) |
|
|
| Completed | 3 | 1811 | Europe, RoW | Triple FF/UMEC/VI, Placebo to match FF/UMEC/VI, Budesonide/Formoterol, Placebo to match Budesonide/Formoterol combination, Albuterol/salbutamol | GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 04/16 | 04/16 | | |
IMPACT, NCT02164513: A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) |
|
|
| Completed | 3 | 10355 | Europe, Canada, Japan, US, RoW | fluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC) | GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 07/17 | 07/17 | | |